Letest Update of Retatrutide: Eli Lilly to File for FDA Approval of Retatrutide, Its “Triple G” Obesity Drug, in Early 2027
On July 23, 2026, Eli Lilly and Company confirmed what much of the obesity-treatment world had been anticipating for months: it will formally file for FDA approval of retatrutide, its next-generation weight loss drug, in the first quarter of 2027. The announcement came alongside two more successful late-stage trials, TRIUMPH-2 and TRIUMPH-3, bringing the drug’s … Read more